ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2011
Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Prognostic and clinical significance of metastasis-associated gene 1 overexpression in solid cancers: A meta-analysis.Medicine · 2018Pooled it
- Integrating the tumor-suppressive activity of Maspin with p53 in retuning the epithelial homeostasis: A working hypothesis and applicable prospects.Frontiers in oncology · 2022Review
- Review
- Cell death pathways and viruses: Role of microRNAs.Molecular therapy. Nucleic acids · 2021Review
- Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.Molecular carcinogenesis · 2020Article
- Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.Journal of cancer research and clinical oncology · 2019Article
- Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis.Journal of breast cancer · 2017Review
- Methylation-induced silencing of maspin contributes to the proliferation of human glioma cells.Oncology reports · 2016Article
- Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.Virchows Archiv : an international journal of pathology · 2016Article
- Review
- Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum.Advances in experimental medicine and biology · 2016Review
- Circulating DNA as biomarker in breast cancer.Breast cancer research : BCR · 2015Review
- miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin.Oncotarget · 2015Article
- Article
- Decreased maspin combined with elevated vascular endothelial growth factor C is associated with poor prognosis in non-small cell lung cancer.Thoracic cancer · 2014Article
- The role of TWIST, SERPINB5, and SERPIN1 genes in uterine leiomyomas.Journal of the Turkish German Gynecological Association · 2014Article
- Role of maspin in cancer.Clinical and translational medicine · 2013Article
- Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC).PloS one · 2013Article
- MTA1 expression correlates significantly with cigarette smoke in non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2011Article
- Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs).Epigenetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maspin is a serine protease inhibitor with tumor-suppressor activity. Maspin can suppress tumor growth and metastasis in vivo and tumor cell motility and invasion in vitro. Previous studies indicate that the loss of Maspin expression is closely linked to aberrant methylation of the Maspin promoter. We examined the promoter methylation status of Maspin in tumor and corresponding serum of breast cancer patients. In addition, protein expression of this gene was also assessed to determine possible correlation between promoter hypermethylation and gene silencing. Further, we investigated the correlation of Maspin expression with vascular endothelial growth factor (VEGF-A) and MTA1 expression. Maspin methylation was analyzed by methylation-specific PCR in 100 invasive ductal breast carcinoma patients' tumors and circulating DNA in a prospective study. Promoter hypermethylation was correlated with expression of the encoded protein in tumors by immunohistochemistry. Significant correlation was observed between promoter hypermethylation of Maspin (r = +0.88; p ≤ 0.0001) in tumors and paired sera. Significant association was found between Maspin promoter hypermethylation and loss of its protein expression (p = 0.01, OR = 3.1, 95% CI = 1.3-7.4). The expression of VEGF-A and MTA1 was lower in tumors with high Maspin expression compared to tumors with loss of Maspin expression. Our results indicate that aberrant promoter methylation is associated with loss of Maspin immunoreactivity in breast cancer tissues. Further, loss of Maspin expression is significantly correlated with increased expression of VEGF-A and MTA1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.